CClinicalTrials.gg
Sign In
CompletedNCT02352506Updated Mar 15, 2023

Serum MIF in Acute Kidney Injury

An observational study in Acute Kidney Injury, sponsored by Medical University of Vienna. Completed at 1 site in Austria. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-03-15.

Sponsored by Medical University of Vienna · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Acute kidney injury (AKI) is a common complication in critical care patients. Currently no parameters are available for early prognosis of AKI. Macrophage migration inhibitory factor (MIF) has been associated with AKI in clinical studies. The aim of this study is to evaluate the time course of MIF concentrations in patients with AKI.

02

Conditions studied

  • Acute Kidney Injury
03

In context

Acute Kidney Injury

1,595 studies on the registry are indexed under Acute Kidney Injury; 371 are open to participants now.

This study's enrollment of 500 is above the median of 150 across 773 observational studies indexed under Acute Kidney Injury.

Browse Acute Kidney Injury studies →

Lead sponsor

Medical University of Vienna is the lead sponsor of 1,076 studies on the registry; 177 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Critical care patients

Eligibility criteria

Exclusion Criteria:

  • Age \< 18 years and > 80 years
  • Patients with chronic dialysis
  • Patients with continuous hemodialysis, hemofiltration or hemodiafiltration within 4 weeks prior to the study
  • Patients with an expected length of ICU stay shorter than 3 days
  • Patients with a low probability of surviving the first 2 days after ICU admission
  • Pregnancy and nursing
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • AKI

    Patients developing AKI during the ICU stay

    Other: Blood draw for measurement of MIF

  • No AKI

    Matched controls not developing AKI during the ICU stay

    Other: Blood draw for measurement of MIF

Interventions

  • OtherBlood draw for measurement of MIF

    Observational study, no intervention

06

What researchers measure

Primary outcomes

  1. Macrophage migration inhibitory factor

    Time frame: Up to 14 days

Secondary outcomes

  1. Serum creatinine

    Time frame: Up to 14 days

07

Study locations

1 site
  • Medical University of Vienna
    Vienna, 1090, Austria
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02352506
Lead sponsor
Medical University of Vienna
Responsible party
David M Baron, MD, PhD (Univ.-Ass., Medical University of Vienna) — Principal investigator
First posted
Feb 2, 2015
Start date
Jan 2015
Primary completion
Nov 2019
Completion
Jan 2023
Last update
Mar 15, 2023
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Acute Kidney Injury→

Other studies from this sponsor

Medical University of Vienna

Start the discussion